Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST)
Early Therapy of Atrial Fibrillation for Stroke Prevention Trial (EAST).
Sponsor: Abbott
Listed as NCT01288352, this PHASE4 trial focuses on Atrial Fibrillation and Stroke and remains completed. Sponsored by Abbott, it has been updated 11 times since 2011, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
11 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Apr 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE4
-
Sep 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE4
-
Jun 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE4
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
-
Feb 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott
- Atrial Fibrillation Network
- BMBF (German Ministry for Science)
- Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- European Heart Rhythm Association (EHRA)
- Sanofi
- The German Heart Foundation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Different, Belgium , Different, Czechia , Different, Denmark , Different, France , Different, Germany , Different, Italy , Different, Netherlands , Different, Poland , Different, Spain , Different, Switzerland and 1 more location